| Osteoarthritis Animation - Video New treatment option for the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis offered pain relief with a built-in proton pump inhibitor (PPI) feedproxy.google.com |
False-Alarm Medical Tests (at Forbes) Some tests pointing to serious conditions are wrong far more often than they are right. Which ones are most likely to cause needless anxiety? us.rd.yahoo.com |
Quest Diagnostics Reports Second Quarter 2010 Financial Results; Updates Guidance for 2010 (PR Newswire) Quest Diagnostics Incorporated , the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. us.rd.yahoo.com |
Aluminum Content of Infant Formula Remains a Challenge for Pfizer Pharmalot submits: A new study finds that the aluminum content of infant formula remains unacceptably high and one of the manufacturers cited is SMA Nutrition, a company based in the UK and owned by Pfizer (PFE). The issue is significant, of course, for public health reasons, but also for Pfizer, which Wall Street projects will derive a growing proportion of revenue from its nutrition business over the next few years. The study (pdf), which was published in BMC Pediatrics, examined 15 infant formulas, including powered and ready-made liquid formulas based on cow’s milk and a soy-based product, for babies at various ages. The researchers found that concentrations of aluminum in the milk formulas varied from 200 to 700 micrograms per liter and would cause up to 600 ug of aluminum to be ingested per day. Put another way, the aluminum content was between 10 and 40 times higher than the aluminum content of breast milk, which is usually 15 to 30 microgram per liter.Complete Story » seekingalpha.com |
PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region [PR Newswire] - PAREXEL International Corporation , a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Nagoya, Japan to support a growing demand for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region. us.rd.yahoo.com |